Cyclooxygenase-2 Inhibitors Down-regulate Osteopontin and Nr4a2-New Therapeutic Targets for Colorectal Cancers

Gastroenterology

Volumn 137, Issue 4, 2009, Pages

  Zagani, Rachid ^a,b   Hamzaoui, Nadim ^a,b   Cacheux, Wulfran ^a,b   de Reyniès, Aurélien ^c   Terris, Benoît ^d   Chaussade, Stanislas ^d   Romagnolo, Béatrice ^a,b   Perret, Christine ^a,b   Lamarque, Dominique ^e  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

^c Ligue Nationale Contre le Cancer   (France)

^d Hôpital Cochin ^*  (France)

^e HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CELL NUCLEUS RECEPTOR; CELL NUCLEUS RECEPTOR 4A2; OSTEOPONTIN; PARECOXIB; ROFECOXIB; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; DOWN REGULATION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTESTINE POLYP; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURVIVAL TIME;

ADENOMATOUS POLYPOSIS COLI; ANIMALS; ANTINEOPLASTIC AGENTS; BETA CATENIN; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC POLYPS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, APC; HUMANS; ISOXAZOLES; LACTONES; MICE; MICE, MUTANT STRAINS; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 2; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPONTIN; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SULFONES; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSFECTION; WNT PROTEINS;

EID: 70349504538     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.06.039     Document Type: Article

References (36)

1. Rostom A., Dube C., Lewin G., et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146 (2007) 376-389
2. Giardiello F.M., Hamilton S.R., Krush A.J., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328 (1993) 1313-1316
3. Waddell W.R., and Loughry R.W. Sulindac for polyposis of the colon. J Surg Oncol 24 (1983) 83-87
4. Arber N., Eagle C.J., Spicak J., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355 (2006) 885-895
5. Bertagnolli M.M., Eagle C.J., Zauber A.G., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355 (2006) 873-884
6. Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340 (1999) 1888-1899
7. Vane J.R., Bakhle Y.S., and Botting R.M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38 (1998) 97-120
8. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
9. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
10. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
11. Cha Y.I., and DuBois R.N. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 58 (2007) 239-252
12. Colnot S., Niwa-Kawakita M., Hamard G., et al. Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers. Lab Invest 84 (2004) 1619-1630
13. Agrawal D., Chen T., Irby R., et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94 (2002) 513-521
14. El-Tanani M.K., Campbell F.C., Kurisetty V., et al. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 17 (2006) 463-474
15. Bellahcene A., Castronovo V., Ogbureke K.U., et al. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8 (2008) 212-226
16. Shen G., Khor T.O., Hu R., et al. Chemoprevention of familial adenomatous polyposis by natural dietary compounds sulforaphane and dibenzoylmethane alone and in combination in ApcMin/+ mouse. Cancer Res 67 (2007) 9937-9944
17. Benhamouche S., Decaens T., Godard C., et al. Apc tumor suppressor gene is the "zonation-keeper" of mouse liver. Dev Cell 10 (2006) 759-770
18. Colnot S., Decaens T., Niwa-Kawakita M., et al. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci U S A 101 (2004) 17216-17221
19. Oshima M., Dinchuk J.E., Kargman S.L., et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 (1996) 803-809
20. Moran A.E., Hunt D.H., Javid S.H., et al. Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J Biol Chem 279 (2004) 43261-43272
21. Buchanan F.G., Holla V., Katkuri S., et al. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res 67 (2007) 9380-9388
22. Rohde F., Rimkus C., Friederichs J., et al. Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int J Cancer 121 (2007) 1717-1723
23. El-Tanani M.K., Barraclough R., Wilkinson M.C., et al. Regulatory region of metastasis-inducing DNA is the binding site for T cell factor-4. Oncogene 20 (2001) 1793-1797
24. El-Tanani M., Platt-Higgins A., Rudland P.S., et al. Ets gene PEA3 cooperates with beta-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription. J Biol Chem 279 (2004) 20794-20806
25. Castellone M.D., Teramoto H., Williams B.O., et al. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310 (2005) 1504-1510
26. Shao J., Jung C., Liu C., et al. Prostaglandin E2 stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer. J Biol Chem 280 (2005) 26565-26572
27. Holla V.R., Mann J.R., Shi Q., et al. Prostaglandin E2 regulates the nuclear receptor NR4A2 in colorectal cancer. J Biol Chem 281 (2006) 2676-2682
28. Lammi J., Huppunen J., and Aarnisalo P. Regulation of the osteopontin gene by the orphan nuclear receptor NURR1 in osteoblasts. Mol Endocrinol 18 (2004) 1546-1557
29. Perlmann T., and Jansson L. A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and NURR1. Genes Dev 9 (1995) 769-782
30. Baron J.A., Sandler R.S., Bresalier R.S., et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131 (2006) 1674-1682
31. AJCC cancer staging manual (2002), Springer-Verlag, New York, NY
32. el Marjou F., Janssen K.P., Chang B.H., et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39 (2004) 186-193
33. Perlmann T., and Wallen-Mackenzie A. Nurr1, an orphan nuclear receptor with essential functions in developing dopamine cells. Cell Tissue Res 318 (2004) 45-52
34. Li Q.X., Ke N., Sundaram R., et al. NR4A1, 2, 3-an orphan nuclear hormone receptor family involved in cell apoptosis and carcinogenesis. Histol Histopathol 21 (2006) 533-540
35. Kinzler K.W., and Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87 (1996) 159-170
36. Kitagawa H., Ray W.J., Glantschnig H., et al. A regulatory circuit mediating convergence between Nurr1 transcriptional regulation and Wnt signaling. Mol Cell Biol 27 (2007) 7486-7496